The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
That trade was at 15.45p so based on the surrounding trades and direction of the SP it was almost certainly a Sell.
The MM's are a canny bunch with their Red and Blue pens........
Chester.
Hi crumbs
Abso-posi-tutely ..........
The fact that Prof Ottensmeiers has agreed to have a quote in his name speaks to his confidence and excitement that ModiFY is the real deal. Maybe something to come from Scancell very shortly, hope so anyway.
Chester.
AB124 do you honestly think that our CEO is not aware of that article. There is no way that permission was granted solely by the Clatterbridge Clinical Trial team.
It's great to see it printed in the Liverpool Echo.
Chester.
A local journalist obviously heard about Trish's story and sought permission to do an article in the Echo. Good job by him.
The fact that the permission has been granted shows that Scancell are finally ready for Trish's trial results to be published beyond the Macmillian pages.
It also suggests that the trial as a whole is much more than just one patient having a remarkable reaction.
This publication is what we have hoped for over the past ten years or so. To see the ModiTope story begin to emerge is fantastic.
Chester.
We cannot be to confident that news will arrive anytime soon, but, to have Prof Christian Ottensmeier, Chief Investigator, University of Liverpool, presenting our abstract at the upcoming ASCO Conference has got to be seen as extremely positive.
He is not going to America to present a trial that is just about showing some promise. He's going because the results being seen in the ModiFY clinical centres are of a such quality that it is worthy of his valuable time and positive enough for him to put his name and reputation against them.
Chester.
Hiya Berm
I am only referencing the confirmed and anecdotal statements attributed to the Macmillan site. The 55% reduction has only been referenced as a partial reduction.
So we know there is anecdotal evidence that Modi1 is performing well in that one patient and possibly stabilising others . Whispers.
The next Scancell ModiFY report should answer a lot of questions being asked.
Chester.
What do we actually know.
The SCIB1 SCOPE trial is progressing but awaits the move up to iSCIB+. As far as we know it is a viable trial with a real world clinical need.
ModiFY is progressing 'very encouragingly' after only 8 weeks of treatment. We have heard whispers of continued good results.
An Abstract to come at ASCO 2023 with our lead Clinical Scientist happily being rolled out to add weight to the message. The trial is probably making headway then?
AvidiMab works ( Covidity Trial Proof ), and if it improves the avidity of any Antibody Drug why would those pharma companies not add it to their products. It also allows for an extended patent, win - win on deployment.
According to GenMab, after investigating our GlyMab Antibody for a few years, our product / target is very exciting and worth £5million in an upfront payment. That's a lot of cash for the very first over the line deal.
I don't care what anyone has said about it could have been higher its the first ever deal on a Scancell GlyMab. Onus in such a scenario is on the seller not the buyer.
We know we have a new Chairman of some high regard.
So apart from what we have not been told, so far, we know there are many positives to the Scancell story and they all point towards a successful investment outcome. Rodders......
Chester.
Hi LochinvarLass
I doubt that a sale of that magnitude would happen before there is convincing evidence that Modi1 works at a commercially profitable percentage level. An early bid from somewhere, at let's say 60p, would probably be rejected by the board.
One option would be that another large investor stumps up £30m or £40m to allow Scancell time to bring all of our assets beyond proof of concept, pushing the company to a point where it is worth a very large number.
That route would mean more dilution. However once success was guaranteed it would mean a much higher SP.
My preferred outcome is that we do raise enough funds by doing deals on AvidiMab and GlyMabs, no dilution, better for the company and ourselves.
Chester.
Hi TF
What we don't know is who is talking to who ?
I think it would be amazing if there were any large pharma companies who are involved in oncology that do not know about Scancell and their novel trial in four hard to treat solid cancers.
As you have said, we can but be patient.
Chester.
Hi Cleanerworld
All my best wishes to you.
I think we actually met at the AGM when we were jointly talking to Lindy Durrant.
You are a valued member of our posting team, fingers crossed for a very positive outcome.
Chester.
Thank you Ray and crumbs, I think you have made me understand the clear difference from the recent Poster Presentation and an Abstract Presentation. The fact that such a well known oncology professor is there on the spot presenting our trial data is a dig deal.
Not wanting to return to hype about Scancell releasing an RNS just prior to this early June conference, but if the lead scientist is going you would think the company will back him up with something in the way of new trial information.
Just saying.....
Chester.
Hi JB1
I can only go off the fact that we had not seen any transactions of that ilk in the days leading up to the 17th and we didn't see any in the days after.
The values match up pretty well, so I'm fairly convinced those trades were RG rasing enough funds to pay Scancell the £129,000 due to them.
If those trades were just coincidence and you are indeed correct, the SP has got to move up pretty rapidly to reach 45p + by the last day of July, and I will drink to that.......
Chester.
Hi crumbs and Ray
So is it a set Abstract from the trial that is presented, as in a printed poster or is it using slides, along with an Oral presentation leading to questions. All done to a strict time slot?
I'm trying to understand if I was there what I would actually see.
Chester.
So there is no misunderstanding this time around I presume an Abstract is one up from a Poster Pesentation. If it's Christian who is the main speaker does an Abstract mean, on stage for a 15 minute talk followed by questions and answers ?
Chester.
Hi JB1
Given that RG had documentary evidence that he owned those shares and they were coming onto the market in a few days time I'm pretty sure he could have agreed a deal.
Unfortunately I have no experience of having to organise such a transaction but it must be a common occurrence for the MM's as this is a standard way of rewarding senior management.
Chester.
Hi JB1
That RNS on the 17th April coincided with 3 large black trades that when totalled came to approx £ 132k .
Richard Goodfellow's Share Options of 2,880,000 x 4.5p / share would cost him £ 129,600 + Brokers Fees.
So I would suggest that those Black Trades on that day points firmly towards RG raising enough funds on the 17th April to
purchase his 2,880,000 shares, which became effective on Thursday 20th April.
This would also mean that there were no performance hurdles put in place when the Options were reissued on 30th July 2020.
Chester.
As we move into a new financial year could that be the catalyst for more information flowing from the company.
Our Chairman arrived on the 1st of February so he will have had three months to absorb the science. He should now be fully up to speed with the many facets of the company and reached a point where his appointment will start to have meaning and impact.
Year end always deflects focus towards tiding up loose ends and ensuring the accounts are fully in order. My hope is that the focus now changes and during May we hear more about the progress of our platforms.
I'm still convinced that we will get the 16 week comparison data on those original 14 patients. It would also be useful to hear how the recruitment is doing in the face of the NHS strikes.
What is happening with the SCOPE Trial ?
Any interest in the Covidity Data ?
Have we seen any interest in AvidiMab ?
How are the collaborations on GlyMabs progressing ?
GenMab 1st Milestone, coming soon ?
This is not a comprehensive list but explains to me why some of us are eager to hear how our investment is developing.
Chester.
I've been out all day so I'm just catching up with the posts. With regards to us investors being kept in the loop with ModiFY Data as it comes in.
At the AGM in November and during the Q&A session Lindy responded to a question about the ModiFY Trial by saying something along the lines of :
The beauty of the Trial Design is that its Open Label which means we can give you regular updates.
I will listen to the recording later to hear her actual words but it was definitely along those lines.
Chester.